Brokerages expect that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will report $14.92 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Aerie Pharmaceuticals’ earnings, with estimates ranging from $11.90 million to $17.25 million. The firm is expected to report its next quarterly earnings report on Wednesday, February 27th.

On average, analysts expect that Aerie Pharmaceuticals will report full-year sales of $22.95 million for the current fiscal year, with estimates ranging from $20.50 million to $25.45 million. For the next year, analysts anticipate that the business will post sales of $118.37 million, with estimates ranging from $100.90 million to $152.30 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Tuesday, November 6th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.33) by ($0.40). The firm had revenue of $7.30 million for the quarter, compared to the consensus estimate of $5.63 million.

A number of equities research analysts have recently issued reports on AERI shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $86.00 target price on shares of Aerie Pharmaceuticals in a report on Friday, August 10th. Cowen upped their target price on shares of Aerie Pharmaceuticals from $100.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, August 9th. HC Wainwright set a $78.00 target price on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 9th. BidaskClub cut shares of Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 7th. Finally, Needham & Company LLC set a $86.00 target price on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 13th. One analyst has rated the stock with a sell rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $82.30.

In other Aerie Pharmaceuticals news, insider Casey C. Kopczynski sold 11,000 shares of the stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $53.87, for a total value of $592,570.00. Following the transaction, the insider now directly owns 139,768 shares of the company’s stock, valued at approximately $7,529,302.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Richard J. Rubino sold 34,512 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $60.17, for a total transaction of $2,076,587.04. Following the completion of the transaction, the chief financial officer now directly owns 383,738 shares in the company, valued at $23,089,515.46. The disclosure for this sale can be found here. Over the last three months, insiders sold 324,117 shares of company stock worth $19,459,226. Insiders own 10.53% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Girard Partners LTD. bought a new position in Aerie Pharmaceuticals in the 3rd quarter valued at about $105,000. Fox Run Management L.L.C. bought a new position in shares of Aerie Pharmaceuticals during the third quarter worth approximately $201,000. First Republic Investment Management Inc. bought a new position in shares of Aerie Pharmaceuticals during the second quarter worth approximately $276,000. Public Employees Retirement Association of Colorado increased its holdings in shares of Aerie Pharmaceuticals by 48.6% during the third quarter. Public Employees Retirement Association of Colorado now owns 4,370 shares of the company’s stock worth $269,000 after purchasing an additional 1,430 shares during the period. Finally, Xact Kapitalforvaltning AB bought a new position in shares of Aerie Pharmaceuticals during the first quarter worth approximately $258,000. 96.43% of the stock is currently owned by hedge funds and other institutional investors.

Shares of AERI stock traded down $2.25 on Friday, reaching $47.76. The stock had a trading volume of 506,285 shares, compared to its average volume of 637,582. The company has a debt-to-equity ratio of 0.64, a quick ratio of 10.07 and a current ratio of 10.27. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -14.17 and a beta of 0.99. Aerie Pharmaceuticals has a 12 month low of $47.06 and a 12 month high of $74.75.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Article: How accurate is the Rule of 72?

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.